NASDAQ:PYXS Pyxis Oncology (PYXS) Stock Price, News & Analysis $2.42 +0.16 (+6.86%) As of 12:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pyxis Oncology Stock (NASDAQ:PYXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pyxis Oncology alerts:Sign Up Key Stats Today's Range$2.24▼$2.7750-Day Range$1.27▼$2.3052-Week Range$0.97▼$5.55Volume1.11 million shsAverage Volume629,191 shsMarket Capitalization$151.78 millionP/E RatioN/ADividend YieldN/APrice Target$6.83Consensus RatingModerate Buy Company Overview Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies. Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens. The company’s proprietary conjugation technology is intended to optimize drug‐to‐antibody ratios and stability in circulation, enabling more efficient tumor penetration and payload release. While most programs are currently in preclinical or Phase I development, Pyxis’s strategic approach seeks to address cancers that have historically proven resistant to standard treatments, including triple‐negative breast cancer and certain gastrointestinal malignancies. Headquartered in Boston, Massachusetts, Pyxis Oncology conducts research and clinical activities across the United States, with plans to expand trials into Europe and Asia as programs advance. The organization draws on expertise from seasoned professionals in oncology drug discovery, translational research and clinical development. Pyxis Oncology continues to collaborate with academic institutions and contract research organizations to accelerate its mission of bringing safer, more effective cancer therapies to patients worldwide.AI Generated. May Contain Errors. Read More Pyxis Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScorePYXS MarketRank™: Pyxis Oncology scored higher than 69% of companies evaluated by MarketBeat, and ranked 174th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingPyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPyxis Oncology has a consensus price target of $6.83, representing about 202.4% upside from its current price of $2.26.Amount of Analyst CoveragePyxis Oncology has only been the subject of 3 research reports in the past 90 days.Read more about Pyxis Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pyxis Oncology are expected to grow in the coming year, from ($1.22) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pyxis Oncology is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pyxis Oncology is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPyxis Oncology has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pyxis Oncology's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.04% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 5.64.Change versus previous monthShort interest in Pyxis Oncology has recently decreased by 14.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPyxis Oncology does not currently pay a dividend.Dividend GrowthPyxis Oncology does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.56 News SentimentPyxis Oncology has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.Search Interest6 people have searched for PYXS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pyxis Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders10.60% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions39.07% of the stock of Pyxis Oncology is held by institutions.Read more about Pyxis Oncology's insider trading history. Receive PYXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PYXS Stock News HeadlinesPyxis Oncology Appoints Nelson Azoulay as Chief Business OfficerMay 7 at 4:05 PM | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 7 at 2:54 AM | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 8 at 1:00 AM | InvestorPlace (Ad)Wedbush initiates coverage of Pyxis Oncology (PYXS) with outperform recommendationMay 5 at 7:39 PM | msn.comPyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026April 17, 2026 | globenewswire.comPyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS)February 5, 2026 | theglobeandmail.comPyxis Oncology Appoints Thomas Civik as Interim CEO Following Leadership TransitionFebruary 3, 2026 | quiverquant.comQSee More Headlines PYXS Stock Analysis - Frequently Asked Questions How have PYXS shares performed this year? Pyxis Oncology's stock was trading at $1.15 on January 1st, 2026. Since then, PYXS stock has increased by 116.1% and is now trading at $2.4850. How were Pyxis Oncology's earnings last quarter? Pyxis Oncology, Inc. (NASDAQ:PYXS) issued its quarterly earnings data on Monday, March, 23rd. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. The firm had revenue of $11.04 million for the quarter, compared to analyst estimates of $0.13 million. When did Pyxis Oncology IPO? Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Wednesday, October 6th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share. Who are Pyxis Oncology's major shareholders? Top institutional investors of Pyxis Oncology include Bank of New York Mellon Corp (0.21%) and Dimensional Fund Advisors LP (0.04%). Insiders that own company stock include Lara Sullivan, Pamela Ann Connealy, Jitendra Wadhane and Rachel Humphrey. View institutional ownership trends. How do I buy shares of Pyxis Oncology? Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pyxis Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Home Depot (HD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings3/23/2026Today5/08/2026Next Earnings (Estimated)5/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PYXS's financial health is in the Green zone, according to TradeSmith. PYXS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PYXS CIK1782223 Webwww.pyxisoncology.com Phone617-221-9059FaxN/AEmployees60Year Founded2019Price Target and Rating Average Price Target for Pyxis Oncology$6.83 High Price Target$8.00 Low Price Target$5.00 Potential Upside/Downside+180.6%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.62 million Net MarginsN/A Pretax Margin-564.55% Return on Equity-101.77% Return on Assets-69.81% Debt Debt-to-Equity RatioN/A Current Ratio3.41 Quick Ratio3.41 Sales & Book Value Annual Sales$13.86 million Price / Sales11.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book2.83Miscellaneous Outstanding Shares62,850,000Free Float56,192,000Market Cap$153.04 million OptionableOptionable Beta1.43 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:PYXS) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PYXS Stock Alerts